235 related articles for article (PubMed ID: 35430987)
1. Favipiravir in SARS-CoV-2 Infection: Is it Worth it?
Batiha GE; Moubarak M; Shaheen HM; Zakariya AM; Usman IM; Rauf A; Adhikari A; Dey A; Alexiou A; Hetta HF; Al-Gareeb AI; Al-Kuraishy HM
Comb Chem High Throughput Screen; 2022; 25(14):2413-2428. PubMed ID: 35430987
[TBL] [Abstract][Full Text] [Related]
2. Revealing the structural and molecular interaction landscape of the favipiravir-RTP and SARS-CoV-2 RdRp complex through integrative bioinformatics: Insights for developing potent drugs targeting SARS-CoV-2 and other viruses.
Chakraborty C; Bhattacharya M; Saha A; Alshammari A; Alharbi M; Saikumar G; Pal S; Dhama K; Lee SS
J Infect Public Health; 2023 Jul; 16(7):1048-1056. PubMed ID: 37196368
[TBL] [Abstract][Full Text] [Related]
3. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
[TBL] [Abstract][Full Text] [Related]
4. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.
Shannon A; Selisko B; Le NT; Huchting J; Touret F; Piorkowski G; Fattorini V; Ferron F; Decroly E; Meier C; Coutard B; Peersen O; Canard B
Nat Commun; 2020 Sep; 11(1):4682. PubMed ID: 32943628
[TBL] [Abstract][Full Text] [Related]
5. Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.
Padhi AK; Dandapat J; Saudagar P; Uversky VN; Tripathi T
FEBS Lett; 2021 Sep; 595(18):2366-2382. PubMed ID: 34409597
[TBL] [Abstract][Full Text] [Related]
6. A review on favipiravir: the properties, function, and usefulness to treat COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1029-1037. PubMed ID: 33372567
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
[TBL] [Abstract][Full Text] [Related]
8. Favipiravir and COVID-19: A Simplified Summary.
Ghasemnejad-Berenji M; Pashapour S
Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367
[TBL] [Abstract][Full Text] [Related]
9. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
Marlin R; Desjardins D; Contreras V; Lingas G; Solas C; Roques P; Naninck T; Pascal Q; Behillil S; Maisonnasse P; Lemaitre J; Kahlaoui N; Delache B; Pizzorno A; Nougairede A; Ludot C; Terrier O; Dereuddre-Bosquet N; Relouzat F; Chapon C; Ho Tsong Fang R; van der Werf S; Rosa Calatrava M; Malvy D; de Lamballerie X; Guedj J; Le Grand R
Nat Commun; 2022 Aug; 13(1):5108. PubMed ID: 36042198
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
[TBL] [Abstract][Full Text] [Related]
11. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
[TBL] [Abstract][Full Text] [Related]
12. Favipiravir in the Battle with Respiratory Viruses.
Smyk JM; Majewska A
Mini Rev Med Chem; 2022; 22(17):2224-2236. PubMed ID: 35184710
[TBL] [Abstract][Full Text] [Related]
13. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase.
Furuta Y; Komeno T; Nakamura T
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(7):449-463. PubMed ID: 28769016
[TBL] [Abstract][Full Text] [Related]
14. Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico.
Sada M; Saraya T; Ishii H; Okayama K; Hayashi Y; Tsugawa T; Nishina A; Murakami K; Kuroda M; Ryo A; Kimura H
Microorganisms; 2020 Oct; 8(10):. PubMed ID: 33092045
[TBL] [Abstract][Full Text] [Related]
15. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
Tsuji M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
[TBL] [Abstract][Full Text] [Related]
16. Favipiravir (T-705), a novel viral RNA polymerase inhibitor.
Furuta Y; Gowen BB; Takahashi K; Shiraki K; Smee DF; Barnard DL
Antiviral Res; 2013 Nov; 100(2):446-54. PubMed ID: 24084488
[TBL] [Abstract][Full Text] [Related]
17. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
[TBL] [Abstract][Full Text] [Related]
18. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
Li J; Zhang C; Wu Z; Wang G; Zhao H
Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
[TBL] [Abstract][Full Text] [Related]
19. Cyanorona-20: The first potent anti-SARS-CoV-2 agent.
Rabie AM
Int Immunopharmacol; 2021 Sep; 98():107831. PubMed ID: 34247016
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019.
Koshi E; Saito S; Okazaki M; Toyama Y; Ishimoto T; Kosugi T; Hiraiwa H; Jingushi N; Yamamoto T; Ozaki M; Goto Y; Numaguchi A; Miyagawa Y; Kato I; Tetsuka N; Yagi T; Maruyama S
CEN Case Rep; 2021 Feb; 10(1):126-131. PubMed ID: 32940880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
